Clinical trials: Membranous
Metastatic Melanoma
Masitinib in Non-Resectable or Metastatic Stage 3/4 Melanoma Carrying a Mutation in the Juxta Membrane Domain of c-Kit
The objective is to assess the efficacy and safety of masitinib at 7.5 mg/kg/day in the treatment of patients with non-resectable or metastatic stage 3 or stage 4 melanoma carrying a mutation in the juxta membrane domain of c-Kit…
- Trial name
- NCT01280565
- Testing
- Masitinib, Dacarbazine
- Where
- 9 sites in United States, Czechia and 5 more
- Volunteers
- 134 people
- Sponsor
- AB Science
CABG-patients, Heart Failure
Safety and Efficacy of Epicardial Implantation of Collagen Membranes With Allogeneic Adipose Derived Stem Cells
The Cardiomesh II clinical trial is a phase I open label study intended to enrol 10 patients to evaluate the safety and efficacy of surgical epicardial implantation of a membrane seeded with allogeneic adipose tissue derived stem…
- Conditions
- CABG-patients, Heart Failure, Myocardial Infarction (MI)
- Trial name
- CARDIOMESH II (NCT06956807)
- Testing
- VB-C01 cellularised patch
- Where
- Poland
- Volunteers
- 10 people
- Sponsor
- Viscofan
Dry Nose, Nose Irritation
Pilot Study to Assess Performance and Safety of SULFEX 13081.22 Nasal Spray in Patients With Dry or Irritated Nose
As the medical device is CE marked, the objective of this study is to provide performance and safety data on SULFEX 13081.22 nasal spray as close as possible to the routine care.
- Trial name
- NCT05499078
- Testing
- SULFEX 13081.22
- Where
- 2 sites in France
- Volunteers
- 40 people
- Sponsor
- Church & Dwight Company, Inc.
Knee Injuries
Large-scale ex Vivo Expansion and Characterization of Two Kinds of MSC From Knee for Clinical Application
According to many researches, mesenchymal stem cells (MSC) isolated from synovial membrane and infrapatellar fat pad have higher ex vivo proliferation capacity, multipotency and ability to undergo chondrogenesis.
- Trial name
- NCT02386163
- Testing
- MSC from synovial membrane and infrapatellar Fat Pad
- Where
- Taiwan
- Volunteers
- 6 people
- Sponsor
- EMO Biomedicine Corporation
Chronic Diabetic Foot Ulcers
Study to Evaluate the Safety and Efficacy of CHAM* for the Treatment of Diabetic Foot Ulcers
A Multicenter, Randomized, Single-Blind Study with an Open-Label Extension Option to Further Evaluate the Safety and Efficacy of Cryopreserved Human Amniotic Membrane for the Treatment of Chronic Diabetic Foot Ulcers
- Trial name
- *OTI-15-01 (NCT02571738)
- Testing
- CHAM, Control
- Where
- 18 sites in United States
- Volunteers
- 108 people
- Sponsor
- Osiris Therapeutics
Advanced Gynecologic Tumors, TIL Engineered With Membrane-Binding Cytokine
A Study of GC203 TIL in Advanced Gynecologic Tumors (10hospital)
This study is to investigate the safety and efficacy on TIL engineered with membrane-binding cytokine (GC203 TIL) for the treatment of patients with advanced gynecologic tumors.
- Conditions
- Advanced Gynecologic Tumors, TIL Engineered With Membrane-Binding Cytokine, Treatment Side Effects, Effects of Immunotherapy
- Trial name
- NCT05468307
- Testing
- Membrane Bound Cytokine Modified TIL
- Where
- China
- Volunteers
- 26 people
- Sponsor
- Shanghai Juncell Therapeutics
Glomerulonephritis, Membranous
Efficacy and Safety Study of Intravenous Belimumab Versus Placebo in Subjects With Idiopathic Membranous Nephropathy
The main clinical study will be a randomized, double-blind, placebo-controlled, long term study involving a 100 week treatment period.
- Trial name
- NCT01762852
- Testing
- Belimumab 10 mg
- Where
- 30 sites in United States, Australia and 8 more
- Sponsor
- GlaxoSmithKline
Diabetic Foot Ulcer
Evaluating the Efficacy NeoThelium FT in the Treatment of Diabetic Foot Ulcers
This is a randomized controlled crossover trial evaluating the efficacy of NeoThelium FT in conjunction with standard of care vs. standard of care alone in treating diabetic foot ulcers.
- Trial name
- NCT06938685
- Testing
- Standard of Care, NeoThelium FT
- Where
- 8 sites in United States
- Volunteers
- 132 people
- Sponsor
- NuScience Medical Biologics, LLC
Exercise-induced Joint Pain Stiffness and Cartilage Turnover
NEM® Versus Placebo on Exercise-induced Joint Pain, Stiffness, & Cartilage Turnover In Healthy, Post-Menopausal Women
This study is intended to evaluate the effect of the dietary supplement NEM® brand eggshell membrane versus placebo in reducing exercise-induced joint pain \& stiffness \& cartilage turnover in healthy post-menopausal women.
- Trial name
- NCT02751944
- Testing
- NEM
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- ESM Technologies, LLC
Primary Membranous Nephropathy
Evaluation of the Efficacy of Zuberitamab Injection in Patients With Primary Membranous Nephropathy
This is a randomized, open-label, cyclosporine-controlled, multicenter Phase III study. It aims to evaluate the efficacy, safety, pharmacokinetics and immunogenicity of zuberitamab versus cyclosporine in patients with primary…
- Trial name
- NCT07830433
- Testing
- Zuberitamab 1000mg, Cyclosporine
- Where
- China
- Volunteers
- 150 people
- Sponsor
- BioRay Pharmaceutical Co., Ltd.
Diabetic Foot Ulcer
Prospective Case Series Evaluating the Efficacy and Safety of NeoThelium FT for Diabetic Foot Ulcers
This is a prospective case series evaluating the efficacy and safety of NeoThelium FT Amnion Skin Graft in the Mangement of Diabetic Foot Ulcers
- Trial name
- NCT07039396
- Testing
- NeoThelium FT (HCT/P 361)
- Where
- 3 sites in United States
- Volunteers
- 10 people
- Sponsor
- NuScience Medical Biologics, LLC
Major Depressive Disorder
A Study of LY03005 vs Pristiq
The objective of this study is to evaluate relative bioavailability between 80 mg LY03005 oral tablets and 50 mg Pristiq® oral tablets after a single dose of each drug in a cross-over 2-period design under fasting condition in…
- Trial name
- NCT03733574
- Testing
- LY03005, Pristiq
- Where
- United States
- Volunteers
- 56 people, healthy volunteers welcome
- Sponsor
- Luye Pharma Group Ltd.
COVID-19
ECMO Braile Biomédica® in COVID-19 Patients
Retrospective data collection to evaluate the gas transfer capacity of the Braile Biomédica® OxyPrime® ECMO BRCoating® Membrane Oxygenator in COVID-19 patients during the pandemic.
- Trial name
- ECMO_COVID (NCT06086405)
- Testing
- Patients underwent cardiorespiratory support
- Where
- Brazil
- Volunteers
- 30 people
- Sponsor
- Braile Biomedica Ind. Com. e Repr. Ltda.
Membranous Nephropathy
Efficacy and Safety of VB119 in Subjects With Membranous Nephropathy
This study is a Phase 1b/2a, open-label, sequential-cohort, dose escalation, and dose expansion study to evaluate the safety, tolerability, PK, and PD of VB119 in subjects with primary MN
- Trial name
- NCT04652570
- Testing
- VB119
- Where
- 4 sites in United States
- Volunteers
- 6 people
- Sponsor
- Tenet Medicines